Notícias

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.72, moving 3.13% from the previous trading session.

In late June 2026, Recursion Pharmaceuticals, Inc. was added to multiple Russell value and small-cap benchmarks, including the Russell 2000 Value Index, expanding its presence in key equity indices. This index inclusion comes as Recursion’s AI‑native drug discovery platform and recent clinical and data‑driven milestones increasingly draw interest from large investors and collaborators. We’ll now examine how this broader index inclusion, alongside Recursion’s AI‑driven discovery progress,...

Recursion Pharmaceuticals has been trying to rebuild momentum after a steep five year decline in shareholder returns, yet its current checks still point to a stock that screens as expensive rather than clearly cheap. Over the past 5 years, Recursion Pharmaceuticals shareholders have seen the stock decline about 90%, which puts extra focus on whether recent optimism is supported by today’s valuation. Progress with the AI driven drug discovery platform and clinical data for REC-4881 can...

Two stocks that have fallen out of favor and one hot stock that was one of Thursday's biggest losers were on the Ark Invest founder's shopping list.

Targeted therapies meet AI-driven discovery as these biotech innovators reveal sharply contrasting financials, risk factors, and industry partnerships.

Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles.

Cathie Wood Loads Up on AI Winners as She Cuts Roku and China Exposure

Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities are emerging far from Silicon Valley. Biotechnology has spent decades producing breakthrough medicines, yet drug development has remained painfully slow, often taking 10 to 15 years while roughly 90% of candidates never reach approval. AI is beginning to change that equation. By ... AI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunity

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?

These aren't for the faint of heart.

Recursion Pharmaceuticals (RXRX) closed at $3.23 in the latest trading session, marking a +2.22% move from the prior day.

Recursion Pharmaceuticals is trying to prove that AI’s next big winner can also come from biotech, and not just from the tech sector.

The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $3.18, representing a -3.34% change from its previous close.

X-Energy Inc. (NASDAQ:XE) is one of the 10 Stocks Stealing the Spotlight from Wall Street Giants. X-Energy saw its share prices increase by 13.50 percent on Monday to end at $21.10 apiece, mirroring the broader market optimism and Cathie Wood’s increased exposure to its stock. Last week, Wood’s global asset management, ARK Invest, announced that […]

Cathie Wood Dumps Tesla. Her New Favorite Is SpaceX

Recursion Pharmaceuticals (RXRX) is back in focus as investors weigh fresh updates on its AI-driven drug discovery platform, along with progress in key clinical assets REC-1245 and REC-4881 and related regulatory discussions. See our latest analysis for Recursion Pharmaceuticals. At a share price of US$3.15, Recursion’s 30 day share price return of 3.28% contrasts with a year to date share price decline of 25% and a 1 year total shareholder return decline of 35.98%. This suggests recent...

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.06, moving 5.12% from the previous trading session.

Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the 9 Stocks Crushing the Market With Surging Returns. Recursion Pharmaceuticals snapped two straight days of losses on Thursday, surging 9.51 percent to close at $3.80 as investors began repositioning portfolios ahead of key business updates next week. In a notice to investors, Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) said […]

In recent days, Recursion Pharmaceuticals reported positive early clinical data and advances in its AI-driven drug discovery pipeline, alongside a narrower-than-expected first-quarter EPS loss and revenue that surpassed expectations, while also filing Form 144 notices for planned insider share sales and issuing multi-year RSU awards to new employees. Together, these developments highlight operational discipline, an extended cash runway into early 2028, and growing reliance on AI tools to...

Recursion Pharmaceuticals (NasdaqGS:RXRX) reported positive early clinical data from its AI driven drug discovery programs. The company highlighted progress in oncology and rare disease candidates in its latest pipeline update. The news focuses on clinical and platform milestones rather than regular earnings or compensation events. Recursion Pharmaceuticals is drawing attention as it pairs artificial intelligence with drug discovery, and its recent clinical update adds fresh detail to that...

Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation.

Formerly known as Verge Genomics, the new Verge Labs will help pharma and biotech partners match potential brain drugs to patients who best benefit from them.

The stock looks cheap, but appearances can be deceiving.

With an upside potential of 99.1% and a relative strength index (RSI) of 33.8, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands out as one of the notable oversold play in the AI sector. While analyst support remains strong, the stock is currently lacking investor confidence. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) fell to a new 52-week low of $2.85 […]

Recursion Pharmaceuticals (RXRX) has been drawing investor attention after recent trading shifts, with the stock closing at US$3.01 and showing mixed performance over the past week, month, and past three months. See our latest analysis for Recursion Pharmaceuticals. Recent trading has been choppy, with the 1 day share price return down 3.22% and the 30 day share price return down 14.24%, while the 1 year total shareholder return has declined 26.23%. This may indicate fading momentum as...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the 10 Best Penny Stocks to Buy for Long Term. On May 14, 2026, Morgan Stanley raised the firm’s price target on Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) to $5.50 from $5 and kept an Equal Weight rating on the shares. On May 6, 2026, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) reported […]

NVIDIA's latest 13F filing does not tell the story it seems to at first glance. The apparent divergence in its CoreWeave and Nebius holdings is a prime example.

With a stock price of $3.32, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the 10 Unrivaled Penny Stocks to Buy Now. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) reported first-quarter revenue of $6.47 million on May 7, below analyst consensus estimates of $15.78 million. The company ended the quarter with approximately $665.2 million in cash, cash equivalents, and restricted cash, […]